Shots:
- Oak Hill Bio has entered into an exclusive license agreement with Roche to obtain global rights of rugonersen (RO7248824) for the treatment of angelman syndrome
- Oak Hill to initiate a pivotal P-III trial of rugonersen for angelman syndrome in early 2026, pending regulatory review of the final trial protocol
- TANGELO study led by Roche, assessed rugonersen (ASO) vs natural history, which showed positive exploratory effects on multiple clinical measures & EEG delta power; data was presented at FAST’s Global Science Summit 2024
Ref: Oak Hill Bio | Image: Oak Hill Bio & Roche
Related News:- Roche’s Columvi (Glofitamab) Regimen Receives the EC’s Approval to Treat R/R Diffuse Large B-Cell Lymphoma (DLBCL)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
